The ability of two glycoproteins of human milk, lactoferrin and free secretory component, to bind to Escherichia coli colonization factors (CFAs) was investigated using immunocytochemistry assays of enriched fimbrial extracts. The results revealed that lactoferrin binds to fimbrial CFA I adhesin but not to CFA II adhesin (CS1 and CS3), while free secretory component interacts with both CFA I and CFA II adhesins. Our data indicate that lactoferrin and free secretory component, which are very abundant proteins of human milk, could play an important role against infant enteric disease by blocking bacterial adhesion. ß
Introduction
Enterotoxigenic Escherichia coli (ETEC) has been considered one of the major cause of diarrhea in children living in developing countries [1, 2] . The ability of many strains of ETEC to adhere and colonize the intestinal mucous membrane of humans has been correlated with the presence of speci¢c ¢mbrial antigens, called colonization factor antigens (CFA) [3] .
CFA I was the ¢rst colonization factor described from human ETEC [3] and it is composed of only one type of subunit [4] . The second colonization factor from ETEC, CFA II [5] , is composed of three distinct E. coli surface antigens (CS), which may be expressed in di¡erent combinations: CS1 and CS3, CS2 and CS3, CS3 only or some rare cases CS2 only [6, 7] . Most of the ETEC strains isolated in Brazil have been shown to possess CFA I or CFA II [8, 9] .
Epidemiological studies of diarrhea have show that breast feeding protects infants from intestinal infections [10, 11] . The protective e¡ect of human milk has been attributed to its immunoglobulin content, mainly to secretory immunoglobulin A (sIgA) [12, 13] , and to non-speci¢c defence factors such as lactoferrin, free secretory component (fSC), lysozyme, bi¢dus factor and oligosaccharides [14^16] .
Lactoferrin is an 80-kDa glycoprotein, found in high concentrations in human milk [15] . Several workers have suggested that lactoferrin has the ability to interact with various components of bacterial surface such as the lipid-A of the lipopolysaccharide [17] and porins [18] . In addition, a study investigating the lactoferrin binding capacity of di¡erent groups of E. coli reveals that ETEC strains had a signi¢cantly higher lactoferrin binding than others groups [19] .
The SC can be found in several secretions complexed with sIgA or as free glycoprotein [20] . It has been shown that fSC is an 80-kDa glycoprotein, which consists of a single polypeptide chain and large amounts of carbohydrate (20%) [21] . There is little information about the role of fSC in secretions but some workers suggest that it may have a protective role against diarrhea [16, 22] .
Previously, we demonstrated that both lactoferrin and fSC inhibit adhesion to erythrocytes by ETEC CFA I strains [16] . To further analyze the role of these com- pounds, we investigated the ability of lactoferrin and fSC to bind to CFA I and CFA II.
Materials and methods

Bacterial strains and culture conditions
The ETEC CFA I and CFA II strains used were TR50/3 (CFA I ST I /LT I O63:H 3 ) and PB176 (CFA II CS1 CS3 ST I /LT I O6:H16), kindly provided by Dr B.C. Guth, Escola Paulista de Medicina, Sa ¬o Paulo, Brazil. These strains have been isolated from children su¡ering from diarrhea and stored frozen. The bacterial cells were grown in CFA agar [3] at 37³C overnight.
Fimbrial puri¢cation
The ¢mbrial puri¢cation was performed as described by Mynott et al. [23] , with some modi¢cations. CFA-positive bacteria were harvested and suspended in phosphate-bu¡-ered saline (PBS). Fimbriae were detached from bacteria by heat treatment in a shaking water bath (60 rev min 31 ) at 65³C for 20 min. Bacterial cells were removed and £uid supernatant was centrifuged at 39 000Ug for 2 h at 4³C to remove outer-membrane contaminants. The resultant £uid supernatant was stored for 48 h at 4³C to allow ¢mbrial aggregation and centrifuged at 167 000Ug for 2 h in a Beckman L5-50B (¢xed rotor 50Ti) ultracentrifuge. The pelleted material containing the partially puri¢ed ¢mbriae, was suspended in 2 ml of PBS supplemented with mannose 1%.
SDS^PAGE and immunoblot analyses
The protein content was measured by method of Bradford [24] and analyzed by SDS^PAGE on acrylamide 12% as described by Laemmli [25] . Gels were stained with Coomassie brilliant blue G (Bio-Rad Laboratories, Hercules, CA, USA).
After electrophoresis, proteins were transferred to nitrocellulose membranes (Trans-Blot SD Semi-Dry CELL, Bio-Rad Laboratories, Hercules, CA, USA) by method of Towbin et al. [26] . The membranes were incubated with speci¢c anti-CFA IgG, anti-rabbit IgG peroxidaseconjugated (Sigma, St. Louis, MO, USA) and reaction was analyzed using ECL detection system (Amersham Life Science, Buckinghamshire, England, UK).
Quantitative analyses of electrophoretic protein pro¢les were obtained by scanning the gels at 340 nm in a CS-9301 PC SHIMADZU computing densitometer.
Antibodies
Polyclonal monospeci¢c rabbit antiserum against CFA I and CFA II (CS1CS3) were also kindly provided by Dr. B.C. Guth, Escola Paulista de Medicina, Sa ¬o Paulo, Brazil. Rabbit anti-lactoferrin serum, goat anti-fSC serum and the secondary antibodies peroxidase-conjugated and goldlabeled were purchased (Sigma, St. Louis, MO, USA).
Puri¢cation of human milk fSC
Fractionation and puri¢cation of fSC was performed as described previously [16] . Brie£y, lipids and casein were removed, and proteins were concentrated by adding ammonium sulfate to 70% ¢nal saturation. The sample obtained was dialyzed and then applied to a Sephacryl S-200 HR column (2.6U80 cm ; Pharmacia Biotech AB, Uppsala, Sweden) equilibrated with Tris^HCl bu¡er, pH 7.6. Thereafter, the fractions of the second peak were applied to a DEAE cellulose column (2.6U30.0 cm ; Sigma, St. Louis, MO, USA) equilibrated with the same bu¡er. For further puri¢cation of fSC, the material eluted in the ¢rst peak after DEAE cellulose chromatography was concentrated, dialyzed and applied to a Heparin^Sepharose a¤n-ity column (1.0U10.0 cm ; Pharmacia Biotech AB, Uppsala, Sweden) equilibrated with Tris^HCl bu¡er, pH 8.0 [16] .
Immunolabeling assay and electron microscopy
For immunogold labeling, the CFA I and CFA II ¢mb-rial preparations were placed on Formvar-carbon-coated grids (200 mesh) (Electron Microscopy Sciences, Fort Washington, USA). Then, grids were treated with antibody anti-CFA I or anti-CFA II and sequentially incubated with anti-rabbit IgG gold-labeled (10 nm gold ; Sigma, St. Louis, MO, USA). Thereafter, ¢mbrial preparations were examined by negative staining.
Binding of glycoproteins to CFAs were determined by an adapted immunological labeling assay using lactoferrin commercially acquired or fSC from human milk at 0.2 mg ml 31 and 0.08 mg ml 31 , respectively. Enriched CFA I (0.7 mg ml 31 ) and CFA II (1.6 mg ml 31 ) ¢mbrial preparations were previously exposed to lactoferrin (Sigma, St. Louis, MO, USA) or fSC for 1 h at room temperature. Subsequently, ¢mbrial suspension were extensively washed with 10 mM Tris^HCl bu¡er, pH 8.0, to remove lactoferrin or fSC that did not bind. Prior to immunolabeling assay, coated grids were incubated for 1 h at room temperature with a blocking solution containing bovine serum albumin 1%, NaCl 0.85% and Tween 20 1% in 10 mM Tris^HCl bu¡er. Thereafter, the grids were placed on a drop of each ¢mbrial preparation, incubated with rabbit anti-lactoferrin serum or goat anti-fSC serum (Sigma, St. Louis, MO, USA), followed by anti-rabbit IgG gold-labeled or antigoat IgG gold-labeled (10 nm gold; Sigma, St. Louis, MO, USA) and negatively stained with phosphotungstic acid 2%, pH 7.2. Subsequently, the grids were examined with a Jeol Jem 100 C electron microscope (Jeol, Japan). 
Results and discussion
Electrophoretic analyses of ultracentrifuge extract obtained from CFA I strain exhibited a major protein band (Fig. 1A, lane 1) , with a molecular mass similar to that of CFA I with a purity of about 93%. The identity of the CFA I band was veri¢ed by immunoblotting assay. Results demonstrated that the protein band with a molecular mass of 16 kDa was recognized by CFA I antiserum (Fig. 1A, lane 2) . SDS^PAGE and immunoblot analyses of enriched ¢mbrial extract CFA II strain (Fig. 1B, lanes 1  and 2, respectively) revealed that CFA II antiserum reacted with proteins of 18.8 kDa and 16.4 kDa, showing that these proteins correspond, respectively, to the CS1 and CS3 components of CFA II. The purity was about 53% to the CS1 component and 3.4% to the protein band corresponding to the CS3 component.
In this study, to determine if lactoferrin binds to CFA I and CFA II, both ¢mbrial preparations were exposed to lactoferrin and afterwards treated with rabbit anti-lactoferrin serum. The CFA I ¢mbrial preparation showed a scattered labeling on the ¢mbriae (Fig. 2C ). This binding pattern was similar to those obtained after the treatment of ¢mbriae with CFA I antiserum ( Fig. 2A) . When whole bacteria were exposed to lactoferrin, similar results were observed. These results revealed that lactoferrin have ability to bind to CFA I ¢mbriae, indicating that this compound may act as a receptor analogue in the inhibition of adhesion of CFA I to the host cell. On the other hand, the binding of lactoferrin to CFA II ¢mbriae (CS1 and CS3) was not demonstrated (Fig. 2D) .
Immunogold assay performed with CFA I and CFA II ¢mbrial preparations exposed to fSC, showed that both CFA I and CFA II ¢mbriae were labeled (Fig. 2E,F) . The observed pattern of gold beads was similar to that found with speci¢c ¢mbrial antibody (Fig. 2B) . A similar result was obtained when the whole bacteria was exposed to fSC. Previously, it was shown that fSC inhibits the adhesion of E. coli CFA I to host cells [16] . These ¢ndings indicate that this glycoprotein could prevent CFA I and CFA II binding to host cells. Furthermore, the ability of fSC to act as a bacterial cell receptor analogue has been reported by Falk et al. [27] and Dallas and Rolfe [28] , working with, respectively, Helicobacter pylori and Clostridium di¤cile.
In conclusion, our results indicate that lactoferrin and fSC, which are very abundant proteins of human milk, could contribute to protection against infant enteric disease by blocking bacterial adhesion, therefore supporting the eventual use of these compounds for prophylactic or therapeutic purposes.
